Immunize

Live Attenuated Influenza Vaccine

search

Live Attenuated Influenza Vaccine, Flumist

  • Indications
  1. See Influenza Vaccine for indications
  2. Was NOT recommended by CDC in 2016 due to lower efficacy
    1. http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html
  3. Alternative option in 2018 for Influenza Vaccine age 2 years to 49 years old who refuse Influenza Vaccine injection
    1. Flumist was previously thought to have higher efficacy than the injection and was preferred ages 2-8 years
    2. Later was thought to have equivalent efficacy as injection, but that is in question as of 2016
  • Contraindications
  1. Includes Influenza Vaccine Contraindications (including severe egg allergy)
  2. Pregnancy
  3. Concurrent Aspirin therapy in age under 18 years (Reye's Syndrome Risk)
  4. Recurrent Wheezing or Asthma
  5. Immuodeficiency
  6. Chronic disease (lung, cardiac, renal, liver, neurologic, hematologic, metabolic)
  7. Exercise caution in severe congestion or acute illness
  • Preparation
  1. Quadrivalent Vaccine only as of 2013 (covers an additional B strain)
  • Dosing
  1. Timing
    1. Same as for TIV Vaccine
    2. May be given as early as July
  2. Dose
    1. One half vial in each nostril
    2. Divider is removed after first half is instilled
  3. Indications for a second dose
    1. First Immunization season
    2. Give second dose before December and at least 28 days after the first
  • Safety
  1. Contains no thimerosol
  • Efficacy
  1. Efficacy expected to be improved against strains in 2018
    1. (2018) Presc Lett 25(8)
  2. In 2016 U.S., intranasal flu Vaccine efficacy has been as low as 3% in children and teens
    1. ACIP does not recommend the intranasal Influenza Vaccine in U.S., 2016
    2. http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html
  3. Initial studies: Moderately more effective than the Inactivated Influenza Vaccine (TIV Vaccine)
    1. Belshe (2007) N Engl J Med 356(7):685-96 [PubMed]
  4. Later observational studies did not demonstrate superiority of Live Vaccine over TIV
    1. http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2014-10.pdf
  • References
  1. (2015) Presc Lett 22(9):49-50